RxDoctor Payments Data

Clan Hahn, MD

Hematology & Oncology · Los Angeles, CANPI 1023043189

Payments from drug & device makers

$13,444in general payments, 2019–2025

Across 519 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Novartis$1K
  • Pfizer$999
  • Merck$836
  • Bristol Myers Squibb$792
  • Regeneron Healthcare Solutions, Inc.$577
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$12,86396%
  • Education$691%
  • Entertainment$140%
  • Other$4994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,444 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$275,688
Medicare patients
261
Services billed
5,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XalkoriCrizotinib12$268,698
RevlimidLenalidomide13$241,761
OpdivoNivolumab19$241,314
GilotrifAfatinib Dimaleate21$239,678
MekinistTrametinib Dimethyl Sulfoxide14$215,157
KeytrudaPembrolizumab19$213,751
TafinlarDabrafenib Mesylate14$200,861
TagrissoOsimertinib Mesylate12$199,674
ImfinziDurvalumab21$197,820
ProcritEpoetin Alfa52$176,578
ErleadaApalutamide12$170,953
Lenalidomide13$153,014
ReblozylLuspatercept-Aamt11$107,706
XgevaDenosumab18$56,154
RetacritEpoetin Alfa-Epbx34$44,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMekinist, Tafinlar$1,117$416,01828 claims
AstraZenecaTagrisso, Imfinzi$551$397,49433 claims
PfizerXalkori, Retacrit, Nivestym, Eliquis$999$349,66579 claims
E.r. Squibb & Sons, L.L.C.Opdivo, Reblozyl$1,722$349,02030 claims
Johnson & JohnsonProcrit, Erleada$393$347,53164 claims
Bristol Myers SquibbRevlimid$792$241,76113 claims
Boehringer IngelheimGilotrif$243$239,67821 claims
MerckKeytruda$836$213,75119 claims
AmgenXgeva, Aranesp, Neupogen$116$137,45153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →